Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 871 AL 885

Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging study

Grosset KA, Malek N, Morgan F, Grosset DG.

Acta Neurol Scand. 2013 Sep;128(3):166-71. doi: 10.1111/ane.12107. Epub 2013 Mar 26.

Athlete's heart patterns in elite rugby players: effects of training specificities

Chevalier L, Kervio G, Corneloup L, Vincent MP, Baudot C, Rebeyrol JL, Merle F, Gencel L, Carré F.

Arch Cardiovasc Dis. 2013 Feb;106(2):72-8. doi: 10.1016/j.acvd.2012.10.002. Epub 2013 Jan 22.

Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study

Pedersen KF, Larsen JP, Tysnes OB, Alves G.

JAMA Neurol. 2013 May;70(5):580-6. doi: 10.1001/jamaneurol.2013.2110.

Advances in electrochemical detection for study of neurodegenerative disorders

Veloso A, Kerman K.

Anal Bioanal Chem. 2013 Jul;405(17):5725-41. doi: 10.1007/s00216-013-6904-3. Epub 2013 Mar 26.

Can mild cognitive impairment in Parkinson disease predict the development of dementia?

Copeland BJ, Schiess MC.

JAMA Neurol. 2013 May;70(5):553-5. doi: 10.1001/jamaneurol.2013.260.

Teaching NeuroImages: pseudo-abnormal DaTscan findings in meningioma-induced parkinsonism

Erro R, Pappatà S, Picillo M, Rocco M, Santangelo G, Barone P, Vitale C.

Neurology. 2013 Mar 26;80(13):e147. doi: 10.1212/WNL.0b013e318289709d.

Ghrelin as a neuroprotective and palliative agent in Alzheimer's and Parkinson's disease

Dos Santos VV, Rodrigues AL, De Lima TC, de Barioglio SR, Raisman-Vozari R, Prediger RD.

Curr Pharm Des. 2013;19(38):6773-90. doi: 10.2174/13816128113199990411.

Defective HIF signaling pathway and brain response to hypoxia in neurodegenerative diseases: not an "iffy" question!

Correia SC, Carvalho C, Cardoso S, Santos RX, Plácido AI, Candeias E, Duarte AI, Moreira PI.

Curr Pharm Des. 2013;19(38):6809-22. doi: 10.2174/1381612811319380013.

Mortalin - a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration

Flachbartová Z, Kovacech B.

Acta Virol. 2013;57(1):3-15. doi: 10.4149/av_2013_01_3.

Validation of an ELISA for urinary dopamine: applications in monitoring treatment of dopamine-related disorders

Nichkova M, Wynveen PM, Marc DT, Huisman H, Kellermann GH.

J Neurochem. 2013 Jun;125(5):724-35. doi: 10.1111/jnc.12248. Epub 2013 Apr 25.

Driving performance and behaviors: a comparison of gender differences in Parkinson's disease

Crizzle AM, Classen S, Lanford D, Malaty IA, Okun MS, Wagle Shukla A, McFarland NR.

Traffic Inj Prev. 2013;14(4):340-5. doi: 10.1080/15389588.2012.717730.

Pisa syndrome in Parkinson's disease: a mobile or fixed deformity?

Doherty KM, Davagnanam I, Molloy S, Silveira-Moriyama L, Lees AJ.

J Neurol Neurosurg Psychiatry. 2013 Dec;84(12):1400-3. doi: 10.1136/jnnp-2012-304700. Epub 2013 Mar 26.

Function and characteristics of PINK1 in mitochondria

Matsuda S, Kitagishi Y, Kobayashi M.

Oxid Med Cell Longev. 2013;2013:601587. doi: 10.1155/2013/601587. Epub 2013 Feb 27.

Recurrent falls in Parkinson's disease: a systematic review

Allen NE, Schwarzel AK, Canning CG.

Parkinsons Dis. 2013;2013:906274. doi: 10.1155/2013/906274. Epub 2013 Mar 5.

Lysosomal enzyme defects and Parkinson disease

Sharma N.

Neurology. 2013 Apr 23;80(17):1544-5. doi: 10.1212/WNL.0b013e31828f1958. Epub 2013 Mar 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias